← Back to Search

GLP-1 Receptor Agonist

Retatrutide for Type 2 Diabetes

Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 40
Awards & highlights

Summary

This trial aims to see if retatrutide is better than a placebo for treating Type 2 Diabetes in patients with poor blood sugar control. It will last around 11 months and participants may need

Who is the study for?
This trial is for adults with Type 2 Diabetes who haven't been able to control their blood sugar levels through diet and exercise alone. Participants should be committed to the study duration of about 11 months and up to 11 visits.Check my eligibility
What is being tested?
The trial is testing the effectiveness and safety of a new medication called Retatrutide compared to a placebo, which has no active ingredients, in managing blood sugar levels in people with Type 2 Diabetes.See study design
What are the potential side effects?
Potential side effects of Retatrutide are not specified here but may include reactions similar to other diabetes medications such as low blood sugar, nausea, digestive issues, or allergic responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 40
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 40 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Secondary outcome measures
Change from Baseline in Body Weight
Change from Baseline in Fasting Serum Glucose
Change from Baseline in Systolic Blood Pressure (SBP)
+10 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Retatrutide Dose Level 3Experimental Treatment1 Intervention
Participants will receive retatrutide administered SC.
Group II: Retatrutide Dose Level 2Experimental Treatment1 Intervention
Participants will receive retatrutide administered SC.
Group III: Retatrutide Dose Level 1Experimental Treatment1 Intervention
Participants will receive retatrutide administered subcutaneously (SC).
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive placebo administered SC.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,629 Previous Clinical Trials
3,217,630 Total Patients Enrolled
11 Trials studying Diabetes
15,619 Patients Enrolled for Diabetes
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
415,996 Total Patients Enrolled
3 Trials studying Diabetes
4,328 Patients Enrolled for Diabetes
~320 spots leftby Jun 2026